Stakeholders call for coordinated action on diagnostics, vaccines, and health system readiness as the monsoon season approaches
Phase 1 dosing is expected to finish by the end of 2025
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Subscribe To Our Newsletter & Stay Updated
